Novo Nordisk failed to disclose {pound}7.8m in payments to doctors and others over three years

Drug company Novo Nordisk has been reprimanded by the UK pharmaceutical regulator after it admitted failing to disclose around £7.8m in payments to 150 recipients including doctors, patients, journalists, and healthcare organisations over a three year period.12In a voluntary admission Novo Nordisk informed the Prescription Medicines Code of Practice Authority (PMCPA) that between 2020 and 2022 it had failed to disclose around 500 payments because of problems with its vendor tagging system. PMCPA is the self-regulatory body that administers the Association of the British Pharmaceutical Industry’s (ABPI) code of practice.The pharmaceutical giant was suspended as a member of ABPI for two years last March after it failed clearly to disclose its sponsorship of a weight management training course for healthcare professionals which included positive information on its obesity drug Saxenda (liraglutide).3In its case report on 5 July PMCPA said the “scale of the undisclosed value identified thus far, over a…
Read Original Article: Novo Nordisk failed to disclose {pound}7.8m in payments to doctors and others over three years »